Royalty Pharma earnings beat by $0.03, revenue topped estimates

Royalty Pharma (RPRX) reported 9% Q3 2026 royalty receipts growth, raising full-year guidance to $3.5-3.55B. ROIC was 14.3%, ROIE 20.2%. Deployed $1.6B in capital, with a 90% success rate in development-stage portfolio. Challenges include a $150M impairment charge from Novartis' pelacarsen failure and declining royalties from key products. Management discussed growth opportunities, including Amgen's olpasiran and China's biotech sector.

Royalty Pharma reported 9% growth in Q3 2026 Portfolio Receipts and raised full-year guidance to $3.5B-$3.55B. The company invested $1.6B in new royalties and returned $590M to shareholders. Management highlighted growth opportunities in pharma R&D co-funding and expansion in China, while maintaining a AAA ESG rating.

Royalty Pharma acquired Zealand Pharma's royalty interest in Takeda's MIMRYLO for $100M, receiving 1% royalties on sales up to $1.5B and 0.75% above that. It also paid AstraZeneca $100M for a 3% royalty on ZORYVE sales. The company reported FDA approvals for RASONQUE and WELTRUZA, and positive phase III results for IMDELLTRA and deucrictibant XR. Royalty Pharma highlighted $1B in R&D co-funding deals, including a $500M agreement with Teva, and expansion in China.

Royalty Pharma (RPRX) reported Q3 2026 earnings, highlighting $1.6B in capital deployment, including acquisitions of royalties on Arcutis' Zoryve and Takeda's Mimrylo. The company raised 2026 guidance, citing strong portfolio performance and positive clinical updates. It returned $590M to shareholders through dividends and buybacks. Management emphasized robust deal pipeline and consistent double-digit growth since IPO.

Royalty Pharma (RPRX) reported Q3 2026 earnings with $890M in portfolio receipts, up 9% YoY. Adjusted EPS of $1.21 beat estimates. The company raised full-year guidance and announced $1.6B in capital deployment, including two new royalty acquisitions. Shares fell 1.81% despite a 79% rally over the past year. The company highlighted strong portfolio growth and pipeline progress, with multiple FDA approvals and positive Phase 3 results.

Royalty Pharma (RPRX) reported Q3 2026 portfolio receipts up 9% to $890M, driven by growth in Tremfya, Voranigo, and Evrysdi. The company raised its FY26 outlook to $3.50B-$3.55B. It deployed $362M in capital, paid dividends, and repurchased shares. RPRX announced several royalty transactions and portfolio updates, including FDA approvals and clinical trial results.